Dr Arora says that the CoWIN portal would not accept the fourth dose.
Bharat Biotech’s iNCOVACC is an adenovirus vectored nasal vaccine.
Bharat Biotech developed the needle-free intranasal vaccine, BBV154, against COVID-19.
Bharat Biotech wants to conduct clinical trials on 5,000 individuals to test its intranasal COVID-19 vaccine.
The government wants to expand the vaccination drive to kids and adolescents also.